Respicardia Closes $58.5 Million In Financing To Treat Central Sleep Apnea
Company announces strategic relationship with ZOLL Medical
December 18, 2017
Company announces strategic relationship with ZOLL Medical
January 6, 2021
Expanded insurance coverage now available in Pennsylvania, Delaware and West Virginia
February 2, 2018
Industry Veteran Peter Sommerness Joins as CEO to Lead U.S. Launch
November 13, 2020
Respicardia, Inc. announced today that Novant Health Forsyth Medical Center in Winston-Salem, NC has treated its 25th patient with the remedē® System, an implantable device that treats central sleep apnea (CSA) by using phrenic nerve stimulation.
December 10, 2020
Respicardia, Inc. announced today that Monument Health in Rapid City, South Dakota is the first center in the Dakotas to treat patients with the remedē® System, an implantable device that uses phrenic nerve stimulation to treat central sleep apnea (CSA).